Smith & Nephew Snats (SNN) has released an update.
Smith & Nephew reported a 4% revenue growth in the third quarter of 2024, reaching $1,412 million, despite challenges in the Chinese market. The company’s 12-Point Plan drove improvements, with significant growth in Advanced Wound Management and Sports Medicine sectors. New product innovations, such as the CATALYSTEM Primary Hip System, continue to enhance their market position.
For further insights into SNN stock, check out TipRanks’ Stock Analysis page.
